EUVIMEDEUVIMED entdecken
Crossref

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment

Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, Atsushi Horiike, Satoshi Wada und 8 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yuya Hirasawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Immune Checkpoint Inhibitors, Neutrophils, Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsImmune Checkpoint InhibitorsNeutrophilsLymphocytesHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overNivolumabAdultLymphocyte CountTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

Immunotherapyesophageal cancerimmune checkpoint inhibitorsneutrophil-to-lymphocyte rationivolumabperformance statuspredictive biomarker

Substanzen

Immune Checkpoint InhibitorsNivolumab

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Department of Clinical Immuno-Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Department of Clinical Diagnostic Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Esophageal Surgery, Showa University Hospital Esophageal Cancer Center, Tokyo, Japan.
  • Pharmacological Research Center, Showa University, Tokyo, Japan.

Zitieren

APA

Hirasawa, Y., Kubota, Y., Mura, E., Suzuki, R., Tsurui, T., Iriguchi, N., Ishiguro, T., Ohkuma, R., Shimokawa, M., Ariizumi, H., Horiike, A., Wada, S., Ariyoshi, T., Goto, S., Otsuka, K., Murakami, M., Kiuchi, Y., Yoshimura, K., Hoffman, R. M., & Tsunoda, T. (2024). Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer Research. https://doi.org/10.21873/anticanres.17160

Vancouver

Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, et al. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer Research. 2024. doi:10.21873/anticanres.17160

BibTeX
@article{Hirasawa2024,
  author = {Hirasawa, Yuya and Kubota, Yutaro and Mura, Emiko and Suzuki, Risako and Tsurui, Toshiaki and Iriguchi, Nana and Ishiguro, Tomoyuki and Ohkuma, Ryotaro and Shimokawa, Masahiro and Ariizumi, Hirotsugu and Horiike, Atsushi and Wada, Satoshi and Ariyoshi, Tomotake and Goto, Satoru and Otsuka, Koji and Murakami, Masahiko and Kiuchi, Yuji and Yoshimura, Kiyoshi and Hoffman, Robert M and Tsunoda, Takuya},
  title = {Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17160}
}
Kostenlos starten →